Penumbra (PEN) Cash from Financing Activities (2014 - 2026)
Penumbra (PEN) reported Cash from Financing Activities of -$1.9 million for Q1 2026, down 170.42% year-over-year from $2.7 million in Q1 2025, and down 137.71% quarter-over-quarter from $5.1 million in Q4 2025.
Penumbra (PEN) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Cash from Financing Activities data on file, last reported at -$1.9 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$1.9 million, down 170.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.9 million (up 126.25% YoY), and the FY2025 annual result was $26.5 million, up 130.49% from the prior year.
- Cash from Financing Activities eased to -$1.9 million in Q1 2026 per PEN's latest filing, from $5.1 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $14.8 million in Q2 2025 and troughed at -$100.6 million in Q3 2024.
- A 5-year average of -$2.0 million and a median of $4.0 million in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 47531.13% in 2024, then surged 441.06% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $5.7 million in 2022, then grew by 3.24% to $5.9 million in 2023, then gained by 2.48% to $6.1 million in 2024, then declined by 16.66% to $5.1 million in 2025, then sank by 137.71% to -$1.9 million in 2026.
- Business Quant data shows PEN's Cash from Financing Activities at -$1.9 million in Q1 2026, $5.1 million in Q4 2025, and $4.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | -2.09 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | -451.20 Mn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 21.00 Mn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -26.93 Mn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | -25.00 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | -97.90 Mn |
| 10 | Penumbra | 12.51 Bn | 11.90 Bn | 253.41 Mn | -1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.91 Mn |
| Mar 31, 2026 | -1.91 Mn |
| Dec 31, 2025 | 5.06 Mn |
| Dec 31, 2025 | 5.06 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Jun 30, 2025 | 14.82 Mn |
| Jun 30, 2025 | 14.82 Mn |
| Mar 31, 2025 | 2.71 Mn |
| Mar 31, 2025 | 2.71 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Sep 30, 2024 | -100.55 Mn |
| Sep 30, 2024 | -100.55 Mn |
| Jun 30, 2024 | 8.27 Mn |
| Jun 30, 2024 | 8.27 Mn |
| Mar 31, 2024 | -794,000.00 |
| Mar 31, 2024 | -794,000.00 |
| Dec 31, 2023 | 5.92 Mn |
| Dec 31, 2023 | 5.92 Mn |